The transcriptional regulator BrlR from Pseudomonas aeruginosa is a member of the MerR family of multidrug transport activators. Studies have shown that BrlR plays an important role in the drug tolerance of P. aeruginosa in biofilms. The tolerance to drugs can be enhanced by 3 0 ,5 0 -cyclic diguanylic acid (c-di-GMP). In the present study, we analyze the apo structure of BrlR and the direct binding between GyrI-like domain of BrlR and P. aeruginosa toxin pyocyanin. Furthermore, we show that pyocyanin can enhance the binding between BrlR and DNA in vitro. These findings suggest that BrlR can serve as the binding partner for both c-di-GMP and pyocyanin.
Pseudomonas aeruginosa infections have a complex pathophysiology and are difficult to eliminate [1] . An intrinsic ability to develop resistance to antibiotics, the formation of impenetrable biofilms and the release of a large quantity of virulence factors all contribute to P. aeruginosa infections. In addition to secreted attacking protein enzymes, including elastase, alkaline protease and LasA protease, many secondary metabolites also are released, which can result in serious damage to the host.
The P. aeruginosa toxin pyocyanin is a blue redoxactive secondary metabolite that can easily penetrate biological membranes, resulting in damage [2, 3] . It is synthesized from chorismate via a series of complex steps mediated by gene products encoded by two phzABCDEFG operons and its precursors are modified into the tricyclic compound by the genes for phzH, phzM and phzS [4, 5] . The synthesis of pyocyanin is regulated by quorum sensing systems, although the details are not clear.
Pyocyanin was reported to kill fungi and Caenorhabditis elegans [6, 7] . Recent studies demonstrated that pyocyanin is required for lung infection in mice [8, 9] . Moreover, large quantities of pyocyanin can be readily recovered from the sputum of patients with cystic fibrosis who have been infected by P. aeruginosa [10] . It has been reported that pyocyanin interferes with multiple cellular functions, resulting in oxidative stress and the inactivation of V-ATPase, as well as a decrease in mitochondrial and cytoplasmic aconitase activity and ATP levels [2, 11] .
Many studies investigating pyocyanin focus on its role in pathogenesis, whereas the regulation and signal transduction pathways have long been ignored. To date, only few pyocyanin receptors have been reported. The human aryl hydrocarbon receptor is a highly conserved ligand-dependent transcription factor that can sense pyocyanin, induce detoxifying enzymes and modulate immune cell differentiation and responses [12] [13] [14] . RmcA from P. aeruginosa comprises a multiple domain protein with both phosphodiesterase and diguanylate cyclase domains, for which activity is modulated by pyocyanin via its PAS domain [15] .
BrlR protein is a transcription regulator in P. aeruginosa. It can only be detected in biofilm cells and is activated by bacterial secondary messenger 3 0 ,5 0 -cyclic diguanylic acid (c-di-GMP) [16] . The activated BrlR can upregulate the expression of multidrug efflux pumps, such as the MexAB-OprM and MexEF-OprN efflux pumps. Knockout of BrlR leads to the susceptibility of the biofilm when the bacteria are treated with five different classes of antibiotics [17] . BrlR belongs to the MerR protein family and consists of three domains, with the middle coiled-coil region flanked by the N-terminal HTH_MerR domain and the GyrI-like domain at the C-terminus. Members of the MerR protein family have been demonstrated to comprise multidrug resistance proteins and some of them can bind potential multidrug molecules directly. In a previous study, we determined the complex structure of BrlR-cdi-GMP and identified one conserved drug-binding pocket. However, so far, there are no studies available in the literature reporting on which small molecule can bind into this pocket and what is the common link between biofilm and multidrug resistance in P. aeruginosa. In the present study, we demonstrate that BrlR from P. aeruginosa is a binding partner for pyocyanin and identify the GyrI-like domain as a potential binding site for pyocyanin.
Materials and methods

Protein expression and purification
Expression and purification of full-length brlR gene and 119-end fragment (GyrI-like domain) were each performed in accordance with a previous protocol [18] . Briefly, the genes encoding the corresponding sequences were amplified by PCR and inserted into the pET-28a vector (Novagen, Madison, WI, USA). The Escherichia coli BL21 (DE3) cells were used as a host for expression. The proteins were obtained by a two-step purification procedure (Ni-affinity and gel filtration purification). The N-terminal His-tag of BrlR removed by thrombin protease before gel filtration was used for crystallization and the N-terminal His-tag of BrlR left intact throughout the purification was used for western blotting. The protein was then concentrated in gel filtration buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 5% glycerol). Protein purity was checked using Coomassie brilliant blue-stained SDS/PAGE. The mutagenesis of BrlR (W150A) was performed by overlap-extension PCR and both the expression and purification of the mutant protein used the same method as that employed for the wild-type.
Crystallization, data collection, structure determination and refinement Purified BrlR proteins were concentrated to~10 mgÁmL À1 in the gel filtration buffer and screened for crystallization using commercially available kits (Molecular Dimensions Ltd, Newmarket, UK). A sitting-drop vapor diffusion method was used in a 24-well Itelli-plate to optimize the crystals at 20°C (10% v/v 1,4-dioxane, 0.1 M Mes/NaOH, pH 6.5, 1.6 M ammonium sulfate; Structure Screen 1 & 2; Molecular Dimensions Ltd). The grown crystals were dehydrated using 1.8 M lithium sulfate to improve the resolution.
The diffraction data were collected on beamline BM14 at the European Synchrotron Radiation Facility (ESRF, Grenoble, France). Macromolecular crystal annealing was performed. Briefly, before data collection, the cold nitrogen stream was blocked for~3 s, on three occasions, at intervals of 5 s [19] . The data were indexed, integrated and scaled with HKL2000 (HKL Research Inc., Charlottesville, VA, USA) [20] . PHASER (PHENIX) was used to perform the molecular replacement [21] . The BrlR coordinate from the c-di-GMP complex structure [Protein Data Bank (PDB) code: 5XQL] was used as the search model. COOT was used to modify the result model and PHENIX.REFINE was used for refinement [21, 22] . The structure of BrlR was deposited in RCSB under PDB code: 5YC9. Crystallographic statistics are summarized in Table 1 . All of the illustrations of the structures were prepared with PYMOL (http://www.pymol.org).
Electrophoretic mobility shift assay (EMSA)
In accordance with previous studies, three DNA probes were designed and labeled with cyanine 5 (Cy5) fluorescent dye (Thermo Fisher Scientific Inc., Waltham, MA, USA; Table S1 ) [17, 23] . The DNA probes (0.5 pmol), BrlR proteins (25 pmol) and different concentration of pyocyanin (Everon Life Sciences, New Delhi, India) were incubated for 30 min at 25°C in binding buffer (10 mM Tris-HCl, pH 7.5, 50 mM KCl, 1 mM EDTA, 1 mM dithiothreitol and 5% glycerol) with a total volume of 20 lL. Then, the samples were subjected to electrophoresis with a 6% polyacrylamide glycine gel using 0.59 TBE running buffer on ice for 80 min. Imaging and data analyses were performed on a Li-Cor imaging system (Li-Cor Biosciences, Lincoln, NE, USA).
Ligand trapping assay
To check the binding between BrlR and pyocyanin, the ligand trapping assay were performed with a 5-kDa cut-off centrifugal filter. BrlR proteins were incubated with its ligand in a 1 : 2 ratio for 20 min at room temperature. Then, BrlR proteins with ligand were concentrated using a centrifugal filter at 4°C for 30 min. The flow-through was collected to measure the concentration of untrapped ligand at a wavelength of 310 nm and the buffer with ligand was used as a control experiment. Every binding assay was repeated at least three times.
Binding affinity measurement
The T m value of BrlR was determined by thermal-denaturation assay with increments of 2°C from 50 to 68°C. Briefly, 20 lg of protein was incubated at denaturing temperature for 3 min followed by centrifugation for 5 min. Then, the supernatant was collected for concentration measurement. The T m (57.5°C) was obtained by fitting the denaturation curve. The BrlR-pyocyanin binding affinity was measured using a ligand concentration-dependent thermal-denaturation assay. The 0.05 lM BrlR protein was incubated with various concentrations of pyocyanin (0.5, 1, 5, 10 and 20 lM) and denatured at 57.5°C for 3 min. The supernatants were collected for western blotting. The protein was detected using primary mouse anti-His antibody (dilution 1 : 5000; Clontech, Palo Alto, CA, USA) and secondary horseradish peroxidase conjugated rabbit antimouse antibody (dilution 1 : 2000; Cell Signaling Technology, Beverly, MA, USA). The image was analyzed using IM-AGEJ (NIH, Bethesda, MD, USA) and dissociation constant (K d ) was calculated with a fitted curve.
Results
Tetrameric apo BrlR structure
The crystal structure of apo BrlR was determined at 2.9 A, with four BrlR molecules in the asymmetry unit. The density is poor around two regions (amino acid residues 27-40 and 137-144) in each protomer because these regions are flexible (Fig. 1A) . According to a previous BrlR-c-di-GMP complex structure, amino acid residues 27-40 take part in c-di-GMP binding and amino acid residues 137-144 are located near the drug-binding pocket [18] . Therefore, both areas show a binding potential for small molecules as a result of their flexibility.
The overall structure of apo BrlR is very much similar to the c-di-GMP bound form. No dramatic conformation difference is observed after c-di-GMP binding and some minor differences may be a result of the crystal packing artifact (Fig. 1B) . Similar to the c-di-GMP bound form, the apo BrlR structure can be divided into three parts: (a) N-terminal HTH_ MerR domain; (b) middle coiled-coil region; and (c) C-terminal GyrI-like domain (Fig. 1) . The apo BrlR exists as a tetramer in solution as revealed in a previous gel filtration experiment [18] .
The c-di-GMP binding did not change the overall conformation and oligomerization state of BrlR (Fig. 1B) . Therefore, the mechanisn by which the c-di-GMP stimulates the BrlR remains elusive.
Pyocyanin binds BrlR in the GyrI-like domain
The similarity and conservation of the GyrI-like domain between BrlR and other multidrug resistance proteins discussed in the previous study [18] indicates that BrlR can bind flat shape molecules (Fig. S1) . For detailed analysis, we compared the GyrI-like domain of BrlR with SAV2435 (PDB code: 5KAU). The GyrIlike domains of BrlR and SAV2435 align well, with an rmsd value of 2.3 A over 165 residues ( Fig. 2A) . Similar to SAV2435, the drug-binding pocket of the BrlR GyrI-like domain is deep and hydrophobic, indicating that this site may have the same preference for small molecules with aromatic rings. Unlike BmrR and SAV2435, which bind many molecules, no small molecules are reported to bind the GyrI-like domain of BrlR so far. We noted that the central xanthene ring of rhodamine 6G (RH6G) in theSAV2435 complex structure is very similar to pyocyanin, which exists in large quantities in P. aeruginosa.
The addition of exogenous pyocyanin can affect the expression of dozens of genes [24] . This may be a result of pyocyanin serving as a redox-active molecule or its direct binding to some transcription factors that cause this regulation. However, to date, no transcription regulators have been identified as pyocyanin receptors. We noted that eight of the upregulated genes encode putative transporters (i.e. the RND transporters mexGHI-opmD, PA3923-3922-opmE and the putative Major Facilitator Superfamily transporter PA3718). The BrlR gene expression level is also upregulated by 2.3-fold. This regulation pattern is somewhat similar to that of the BrlR gene regulation by c-di-GMP. In addition, BrlR will activate genes encoding the MexAB-OprM and MexEF-OprN multidrug efflux pumps after stimulation by c-di-GMP [17] . Under such conditions, we hypothesize that BrlR can bind pyocyanin and trigger its gene regulatory function.
To better characterize the binding property of BrlR towards pyocyanin, we modelled the pyocyanin into the surface cavity of the GyrI-like domain in silicon according to the binding mode of RH6G in SAV2435 (Fig. 2B,C) . The results obtained show that both RH6G and pyocyanin are buried in the cavity of the drug-binding pocket, with several aromatic residues around them. Similar to Trp34 in SAV2435, Trp150 forms stacking interactions with pyocyanin in this model. At the same time, Tyr249 forms hydrogen bonds with pyocyanin, which plays a role in its binding specificity (Fig. 2C) . To confirm this hypothesis, we tested the binding between BrlR protein and pyocyanin using a ligand trapping assay. Figure 2D clearly shows that BrlR can bind pyocyanin and reduce its chance to flow through the filter membrane. The binding also changes the color of the solution from blue to green, especially under more concentrated conditions (Fig. S2 ). The T m value of BrlR is 57.5°C and 20 lM pyocyanin can increase this to 61.5°C (Figs 2E and S2 ). To test whether pyocyanin binding pocket is located in our predicted site in the C-terminal GyrI-like domain, we used the C-terminal part of BrlR for this binding assay and found that it binds pyocyanin much better than the full-length protein, indicating that the full-length protein may be in a more regulated conformation (Fig. 3D) . The binding affinity between BrlR and pyocyanin is~0.75 lM (Figs 2F and S2) , which is comparable to the binding affinity of c-di-GMP (2.2 lM) [16] . However, the binding between the W150A mutation protein and pyocyanin is decreased, as shown by the ligand trapping assay (Fig. 2D) , which suggests that the predicted binding site is correct.
Pyocyanin can enhance the DNA binding of BrlR
BrlR can bind to its own promoter (PbrlR) and the promoter of mexA (PmexA) and mexE (PmexE) [17] . Although c-di-GMP can enhance this binding, we speculate that pyocyanin could function in the same way. To characterize the effect of pyocyanin binding, we performed electrophoretic mobility shift assay (EMSA) assays of BrlR with Cy5 labeled PbrlR, PmexA and PmexE using different concentrations of pyocyanin (Fig. 3) . Because of chemical activity, we checked the effect of pyocyanin on Cy5 labeled DNA (Fig. S3 ). It appears that pyocyanin can quench the Cy5 fluorescent signals, especially at a high concentration. Although the DNA binding of apo BrlR is weak, an increased pyocyanin concentration can enhance the binding of BrlR towards PbrlR, PmexA and PmexE. Because BrlR can nonspecifically bind many dyes (data not shown), we use unlabeled PbrlR, PmexA and PmexE to demonstrate the specificity (Figs 3B and S4). In our assays, a high concentration of unlabeled PbrlR, PmexA and PmexE can successfully compete the BrlR protein, which indicates that the labelling dye does not disturb our EMSA assays. A failure to obtain the complex structure of BrlR and pyocyanin means that the activation mechanism remains unknown. In our size-exclusion chromatography experiments, the apo and pyocyanin bound forms of BrlR share the same elution time, which suggests that pyocyanin does not change the oligomeric sate of BrlR, similar to the c-di-GMP (Fig. S5) . The W150A mutation that lost pyocyanin binding shows a compromised binding ability to PbrlR, PmexA and PmexE DNA in the presence of pyocyanin (Figs 3C and S4) . In sum, these data show that pyocyanin can bind and regulate the transcription factor BrlR.
Discussion
The second messenger c-di-GMP can promote the biofilm formation in P. aeruginosa and the BrlR protein can only be detected after biofilm formation. The binding of pyocyanin or c-di-GMP by BrlR leads to the expression of the BrlR gene and BrlR regulated multidrug efflux pump genes [17] . It appears that both of these small molecules contribute to the multidrug resistance of P. aeruginosa. As a result of the unknown BrlR-ligand-DNA ternary complex structure, the molecular mechanism responsible for BrlR stimulation by c-di-GMP or pyocyanin remains elusive.
In summary, our data suggest that BrlR is a binding partner for both c-di-GMP and pyocyanin. As an unusual transcription regulator, BrlR has two separate binding sites with respect to c-di-GMP and pyocyanin. Future studies aim to focus on the physiological significance of the binding between BrlR and pyocyanin. BrlR appears to represent a promising drug target for the cure of intractable P. aeruginosa infections.
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